hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06282549, orgStudyIdInfo id: YMC046, briefTitle: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-06-08, primaryCompletionDateStruct date: 2027-03-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Yuhan Corporation, class: INDUSTRY, descriptionModule briefSummary: This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination., conditionsModule conditions: Essential Hypertension, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1210, type: ESTIMATED, armsInterventionsModule interventions name: Telmisartan/Amlodipine/Chlorthalidone(Truset), outcomesModule primaryOutcomes measure: Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events), secondaryOutcomes measure: Percentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) in patients with asymptomatic target organ damage, secondaryOutcomes measure: Mean Systolic Blood Pressure (MSBP)/ Diastolic Blood Pressure (MDBP), secondaryOutcomes measure: Patients Achieving the treatment goal in Mean Systolic Blood Pressure (MSBP), secondaryOutcomes measure: Percentage of patients who terminated the treatment, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Busan Veterans Hospital, status: RECRUITING, city: Busan, zip: 46996, country: Korea, Republic of, contacts name: Jonghyun Choi, role: CONTACT, geoPoint lat: 35.10278, lon: 129.04028, locations facility: Daegu Veterans Hospital, status: RECRUITING, city: Daegu, zip: 42835, country: Korea, Republic of, contacts name: Sangwook Kang, role: CONTACT, geoPoint lat: 35.87028, lon: 128.59111, locations facility: Gwangju Veterans Hospital, status: RECRUITING, city: Gwangju, zip: 62284, country: Korea, Republic of, contacts name: Seowon Choi, role: CONTACT, geoPoint lat: 35.15472, lon: 126.91556, locations facility: Konkuk University Medical Center, status: RECRUITING, city: Seoul, zip: 05030, country: Korea, Republic of, contacts name: Chanhee Kwon, role: CONTACT, geoPoint lat: 37.566, lon: 126.9784, locations facility: Veterans Health Service Medical Center, status: RECRUITING, city: Seoul, zip: 05368, country: Korea, Republic of, contacts name: Changhoon Lee, role: CONTACT, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06282536, orgStudyIdInfo id: LungMate-018, briefTitle: Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2029-12, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Shanghai Pulmonary Hospital, Shanghai, China, class: OTHER, descriptionModule briefSummary: Fusion of anaplastic lymphoma kinase (ALK) is an important driving gene for NSCLC, with an incidence rate of 3-7%. In patients with advanced ALK mutation NSCLC, first-line use of ALK inhibitors significantly improves progression free survival. The perioperative research on ALK positive NSCLC was relatively late, and currently most studies mainly focus on early to mid stage ALK positive NSCLC patients. The results of two Phase III clinical trials showed that second-generation ALK targeted drugs, neoadjuvant and/or adjuvant therapy for ALK positive NSCLC, significantly prolonged DFS in patients, including increased pathological response rate, median response duration, and prolonged OS. For ALK positive advanced NSCLC patients who are resistant to second-generation ALK targeted drugs, there is currently limited exploration and there is an urgent need for new exploratory clinical studies.This trial aims to evaluate the effectiveness of Iruplinalkib neoadjuvant therapy for potentially resectable ALK positive non-small cell lung cancer., conditionsModule conditions: Potentially Resectable ALK Positive Non-Small Cell Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: All enrolled patients received Iruplinalkib neoadjuvant therapy., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Iruplinalkib, interventions name: surgery, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Pathologic complete response (PCR) rate, secondaryOutcomes measure: Major pathologic response (MPR) rate, secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Event-free survival (EFS), secondaryOutcomes measure: Treatment-related adverse event (TRAE), secondaryOutcomes measure: 5-year overall survival (OS), secondaryOutcomes measure: 1-year event-free survival (EFS) rate, secondaryOutcomes measure: Health related quality of life (HRQol), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06282510, orgStudyIdInfo id: 23053003, briefTitle: Nasal Antisepsis for C. Auris Prevention, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-29, primaryCompletionDateStruct date: 2026-12, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Mary K Hayden, class: OTHER, collaborators name: Rush University Medical Center, collaborators name: RML Specialty Hospital, descriptionModule briefSummary: This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris., conditionsModule conditions: Candida Auris Infection, conditions: Colonization, Asymptomatic, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Povidone Iodine Topical, outcomesModule primaryOutcomes measure: Detection of C. auris from the anterior nares, secondaryOutcomes measure: Detection of C. auris from body sites other than anterior nares, secondaryOutcomes measure: Detection of C. auris from environmental surfaces, secondaryOutcomes measure: Detection of methicillin-resistant Staphylococcus aureus (MRSA) from body sites other than anterior nares, secondaryOutcomes measure: Detection of MRSA from environmental surfaces, otherOutcomes measure: Non-susceptibility of C. auris to povidone iodine, otherOutcomes measure: Change in microbiome community, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rush University Medical Center, status: RECRUITING, city: Chicago, state: Illinois, zip: 60612, country: United States, contacts name: Sarah E Sansom, DO, role: CONTACT, phone: 312-563-6201, email: sarah_e_sansom@rush.edu, contacts name: Mary K Hayden, MD, role: CONTACT, phone: 312-942-8727, email: mhayden@rush.edu, geoPoint lat: 41.85003, lon: -87.65005, locations facility: RML Specialty Hospital, status: RECRUITING, city: Chicago, state: Illinois, zip: 60624, country: United States, contacts name: Nidhi Undevia, MD, role: CONTACT, phone: 630-286-4000, email: nundevia@rmlspecialtyhospital.org, contacts name: Lisa Duffner, role: CONTACT, phone: 630-286-4000, email: LMikolajewski@rmlspecialtyhospital.org, geoPoint lat: 41.85003, lon: -87.65005, locations facility: RML Specialty Hospital, status: RECRUITING, city: Hinsdale, state: Illinois, zip: 60521, country: United States, contacts name: Nidhi Undevia, MD, role: CONTACT, phone: 630-286-4000, email: nundevia@rmlspecialtyhospital.org, contacts name: Lisa Duffner, role: CONTACT, phone: (630) 286-4000, email: LMikolajewski@rmlspecialtyhospital.org, geoPoint lat: 41.80086, lon: -87.93701, hasResults: False
protocolSection identificationModule nctId: NCT06282497, orgStudyIdInfo id: ZSCPH-003, briefTitle: Xerostomia-optimised IMRT Versus Standard IMRT in NPC, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-23, primaryCompletionDateStruct date: 2026-10-23, completionDateStruct date: 2029-10-23, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Zhongshan People's Hospital, Guangdong, China, class: OTHER, descriptionModule briefSummary: This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of xerostomia-optimized intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in NPC patients, conditionsModule conditions: Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 524, type: ESTIMATED, armsInterventionsModule interventions name: Optimised neck CTV, interventions name: standard neck CTV, outcomesModule primaryOutcomes measure: Regional recurrence free survival, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Local recurrence free survival, secondaryOutcomes measure: Distant metastasis-free survival, secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Acute toxicities, secondaryOutcomes measure: Late toxicities, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhongshan City People's Hospital, status: RECRUITING, city: Zhongshan, state: Guangdong, zip: 528403, country: China, contacts name: Gui-qiong Xu, MD, role: CONTACT, phone: +8613528109888, email: donna_shee@163.com, geoPoint lat: 21.31992, lon: 110.5723, hasResults: False
protocolSection identificationModule nctId: NCT06282484, orgStudyIdInfo id: KY20232348-C-1, briefTitle: A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-01, primaryCompletionDateStruct date: 2023-06-01, completionDateStruct date: 2023-09-29, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Xijing Hospital of Digestive Diseases, class: OTHER, descriptionModule briefSummary: To explore the effects of gastric xanthoma on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer., conditionsModule conditions: Gastric Xanthoma, conditions: Helicobacter Pylori Infection, conditions: Gastric Cancer, conditions: Intestinal Metaplasia, conditions: Precancerous Lesions, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 1260, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: corelation between the gastric xanthoma and gastric mucosa diseases, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xijing Hosipital of Digestive Disease, city: Xi'an, state: Shaanxi, zip: 710032, country: China, geoPoint lat: 34.25833, lon: 108.92861, hasResults: False
protocolSection identificationModule nctId: NCT06282471, orgStudyIdInfo id: MCC-23-20794, secondaryIdInfos id: HM20028614, type: OTHER, domain: Virginia Commonwealth University, briefTitle: EW and Self-Guided PST in Cancer Survivors and Caregivers, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Virginia Commonwealth University, class: OTHER, descriptionModule briefSummary: To assess the feasibility and acceptability of expressive writing + problem solving therapy (EW+PST) among cancer survivors and informal caregivers, conditionsModule conditions: Cancer Survivors, conditions: Informal Caregivers, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Expressive Writing and Problem-Solving Therapy (EW+PST), outcomesModule primaryOutcomes measure: Consent Rate, primaryOutcomes measure: Study Retention, primaryOutcomes measure: Completed Journal Entries, primaryOutcomes measure: Patient Satisfaction Questionnaire, secondaryOutcomes measure: Change in Post Traumatic Growth Inventory (PTGI) Score from 0 to 6 weeks, secondaryOutcomes measure: Change in European Organization for the Research and Treatment of Life Questionnaire (EORTC QLQ-30) Score from 0 to 6 weeks, secondaryOutcomes measure: Change in Patient Health Questionnaire-8 (PHQ-8) Score from 0 to 6 Weeks, secondaryOutcomes measure: Change in Perceived Stress Scale-10 item (PSS-10) Score from 0 to 6 Weeks, secondaryOutcomes measure: Change in New General Self-Efficacy Scale (GSES-N) Score from 0 to 6 Weeks, secondaryOutcomes measure: Change in Multidimensional Scale of Perceived Social Support (MSPSS) Score from 0 to 6 Weeks, secondaryOutcomes measure: Change in Family Environment Scale-Revised (FES-R) Score from 0 to 6 Weeks, secondaryOutcomes measure: Change in Cancer Communication Assessment Tool for Patients and Families (CCAT-PF) Score from 0 to 6 Weeks, secondaryOutcomes measure: Change in Caregiver Burden Scale (CBS) Score from 0 to 6 Weeks, secondaryOutcomes measure: Change in EORTC Quality of Life Core Scale (EORTC QLQ-30) Score from 0 to 6 Weeks, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Virginia Commonwealth University, status: RECRUITING, city: Richmond, state: Virginia, zip: 23298, country: United States, contacts name: Kendra Rowe, role: CONTACT, phone: 804-828-1965, email: rowek2@vcu.edu, contacts name: Massey CPC Team, role: CONTACT, phone: 804-828-1965, email: MasseyCPC@vcu.edu, contacts name: Susan Hong, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.55376, lon: -77.46026, hasResults: False
protocolSection identificationModule nctId: NCT06282445, orgStudyIdInfo id: K2024035, briefTitle: Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine, class: OTHER, descriptionModule briefSummary: To evaluate the efficacy and safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer., conditionsModule conditions: Colorectal Cancer Metastatic, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Adebrelimab, interventions name: Oxaliplatin, interventions name: Capecitabine, interventions name: Bevacizumab, outcomesModule primaryOutcomes measure: Progression-free survival, secondaryOutcomes measure: Organ retention rate, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: Disease Control Rate, secondaryOutcomes measure: Surgical conversion rate, secondaryOutcomes measure: TRAEs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Fourth Affiliated Hospital Zhejiang University School of Medicine, status: RECRUITING, city: Jinhua, state: Zhejiang, zip: 322000, country: China, contacts name: Qijia Xuan, MD&Phd, role: CONTACT, geoPoint lat: 29.10678, lon: 119.64421, hasResults: False
protocolSection identificationModule nctId: NCT06282432, orgStudyIdInfo id: RP-L201-0121-LTFU, briefTitle: Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I), statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2022-03-09, primaryCompletionDateStruct date: 2037-03, completionDateStruct date: 2037-03, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Rocket Pharmaceuticals Inc., class: INDUSTRY, descriptionModule briefSummary: This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene, conditionsModule conditions: Leukocyte Adhesion Deficiency, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Hematopoietic stem cell transplant (HSCT) free survival, secondaryOutcomes measure: Incidence of hospitalizations, secondaryOutcomes measure: Incidence of significant infections, secondaryOutcomes measure: Resolution of LAD-I-related skin rash, secondaryOutcomes measure: Resolution of LAD-I-related periodontal abnormalities, secondaryOutcomes measure: Event free survival, secondaryOutcomes measure: Overall Survival, secondaryOutcomes measure: Long-term genetic correction in peripheral blood mononuclear cells (PBMCs), secondaryOutcomes measure: Long-term genetic correction in PB CD15+ granulocytes, secondaryOutcomes measure: Long-term CD18 neutrophil expression by flow cytometry, secondaryOutcomes measure: Long-term CD11 neutrophil expression by flow cytometry, secondaryOutcomes measure: Improvement or resolution of LAD-I related neutrophilia, secondaryOutcomes measure: Improvement or resolution of LAD-I-related leukocytosis., secondaryOutcomes measure: Incidence of Investigational Product (IP) related serious adverse events (SAEs), secondaryOutcomes measure: Incidence of hematologic malignancy, eligibilityModule sex: ALL, minimumAge: 3 Months, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, Los Angeles (UCLA), city: Los Angeles, state: California, zip: 90095-1489, country: United States, geoPoint lat: 34.05223, lon: -118.24368, locations facility: Hospital Infantil Universitario Niño Jesús, city: Madrid, zip: 28009, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, locations facility: University College London Great Ormond Street Institute of Child Health (GOSH), city: London, zip: WC1N 1EH, country: United Kingdom, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06282406, orgStudyIdInfo id: N4532-R, secondaryIdInfos id: I0X1RX004532, type: OTHER_GRANT, domain: U.S. Department of Veterans Affairs, briefTitle: Pupil-Indexed Noninvasive Neuromodulation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-03, primaryCompletionDateStruct date: 2028-04-03, completionDateStruct date: 2028-08-05, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: VA Office of Research and Development, class: FED, descriptionModule briefSummary: Vagus nerve stimulation (VNS) is thought to activate neural pathways that release chemicals which promote plasticity and learning. Previous work has shown that the auricular branch of the vagus nerve innervates landmarks on the external ear. Work from the PI's laboratory has shown that electrical current applied to the external ear modulates physiological indexes of brain states implicated in the therapeutic effects of VNS. The broad objective of this project is to better understand physiological mechanisms modulated by auricular stimulation to support possible therapeutic effects in the form of motor learning., conditionsModule conditions: Paresis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Subjects will be randomized into one of 5 groups and receive the designated stimulation/sham during a training protocol designed to facilitate motor learning., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: Transcutaneous Electrical Stimulation, interventions name: Sham, outcomesModule primaryOutcomes measure: Force Control Change, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, city: Pittsburgh, state: Pennsylvania, zip: 15240, country: United States, contacts name: Elizabeth B Toth, BA, role: CONTACT, phone: 412-954-5382, email: elizabeth.toth2@va.gov, contacts name: Kimberly A Toland, role: CONTACT, phone: (412) 215-5084, email: Kimberly.Toland@va.gov, contacts name: Michael A. Urbin, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.44062, lon: -79.99589, hasResults: False